Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance

Cellebrite DI Ltd. (NASDAQ: CLBT) reported Q2 EPS of $0.11, $0.04 better than the analyst estimate of $0.07. Revenue for the quarter came in at $131.14 million versus the consensus estimate of $131.87 million.

GUIDANCE:

Cellebrite DI Ltd. sees Q3 2026 revenue of $145-148 million, versus the consensus of $150.3 million.

Cellebrite DI Ltd. sees FY2026 revenue of $550-560 million, versus the consensus of $568 million.

For earnings history and earnings-related data on Cellebrite DI Ltd. (CLBT) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c